Trace Neuroscience launched in 2024 to expand genomic medicine for neurodegenerative diseases, headquartered in South San Francisco, CA. Its lead program is an antisense oligonucleotide (ASO) designed to bind UNC13A mRNA, correct improper splicing, and preserve or potentially improve muscle function in people living with ALS. The company cites UNC13A as a genetically validated target that is insufficient in approximately 97% of people with ALS and linked to disease progression and survival. Trace also sees potential to treat frontotemporal dementia and many Alzheimer’s patients where TDP-43 pathology leads to UNC13A loss. The team comprises academic co-founders and experienced neuroscience drug developers and company builders, and leadership includes clinicians and a senior development sciences group. Financially, Trace launched with a $101 million Series A to advance its lead ASO toward the clinic.

Total raised

$101M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2024